GSK Announces Discontinuation Of Serevent MDI (Green Inhaler), Australia

Main Category: Respiratory / Asthma
Article Date: 28 Sep 2007 - 14:00 PDT

email to a friend   printer friendly   opinions  

GlaxoSmithKline Australia (GSK) has advised all pharmacists today that the Serevent (salmeterol xinafoate) Metered Dose Inhaler (MDI) will be discontinued as of 31st December 2007 as its CFC propellant is being phased out in accordance with International Standards.

The Serevent Accuhaler continues to be available for the treatment of COPD and asthma and GSK is committed to its ongoing supply. Where appropriate, this may be considered as an alternative for those patients currently on Serevent MDI therapy.

GSK recognises the vital role pharmacists will play in assisting patients during their transition and in referring patients to their doctor for review. In accordance with TGA guidelines, the timeframe for discontinuation should allow sufficient time for the review of Serevent MDI customers.

Serevent MDI will be delisted from the Pharmaceutical Benefits Scheme as of the 1st May 2008. A return policy will apply to all Serevent MDI stock remaining in pharmacies after the 1st May 2008. Pharmacies with unsold stock should return it to their preferred wholesaler by 1st June 2008. Stock returned after this date will not be credited. The expiry date of all remaining Serevent MDI inhalers is 2 July 2009.

Pharmacists with product-related queries can contact the GSK Medical Information Line on 1800 033 109. For supply related questions, pharmacists can contact GSK's customer service department on (03) 9721 8600.

http://www.psa.org.au

• Additional
• References
• Citations